CARM — Carisma Therapeutics Share Price
0.000.00%
Last trade - 00:00- $45.70m
- -$8.56m
- $14.92m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.89 | ||
| Price to Tang. Book | 3.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -140.58% | ||
| Return on Equity | -167.51% | ||
| Operating Margin | -565.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 11.24 | 26.54 | 40 | 14.92 | 15.52 | 9.6 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -77.87 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Directors
- Jay Duker NEC (62)
- Thomas Cannell PRE (59)
- Monica Forbes CFO (45)
- Glen MacDonald CTO (63)
- Elly Ryu CAO (40)
- Mark Sullivan GCN (49)
- Peter Honig DRC (61)
- Michael Jewett DRC
- Carrie Bourdow IND (58)
- Jason Keyes IND (50)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 25th, 2008
- Public Since
- February 6th, 2014
- No. of Shareholders
- 42
- No. of Employees
- 107
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 41,542,744
- Address
- 245 1st St Ste 1800, CAMBRIDGE, 02142-1292
- Web
- https://sesenbio.com/
- Phone
- +1 6174448550
- Auditors
- KPMG LLP
Upcoming Events for CARM
Q3 2024 Carisma Therapeutics Inc Earnings Release
Similar to CARM
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Carisma Therapeutics share price?
As of Today at 19:49 UTC, shares in Carisma Therapeutics are trading at $1.02. This share price information is delayed by 15 minutes.
How has the Carisma Therapeutics share price performed this year?
Shares in Carisma Therapeutics last closed at $1.02 and the price had moved by -88.82% over the past 365 days. In terms of relative price strength the Carisma Therapeutics share price has underperformed the S&P500 Index by -91.1% over the past year.
What are the analyst and broker recommendations for Carisma Therapeutics?
The overall consensus recommendation for Carisma Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Carisma Therapeutics dividend yield?
Carisma Therapeutics does not currently pay a dividend.
Does Carisma Therapeutics pay a dividend?
Carisma Therapeutics does not currently pay a dividend.
When does Carisma Therapeutics next pay dividends?
Carisma Therapeutics does not currently pay a dividend.
How do I buy Carisma Therapeutics shares?
To buy shares in Carisma Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Carisma Therapeutics?
As of the previous close price of $1.02, shares in Carisma Therapeutics had a market capitalisation of $42.37m.
Where are Carisma Therapeutics shares listed?
Here are the trading details for Carisma Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CARM
What kind of share is Carisma Therapeutics?
Based on an overall assessment of its quality, value and momentum Carisma Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Carisma Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Carisma Therapeutics is $8.83. That is 765.69% above the last closing price of $1.02.
Analysts covering Carisma Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.26 for the next financial year.
What is the trend in the Carisma Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Carisma Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -71.34%.
As of the last closing price of $1.02, shares in Carisma Therapeutics were trading -59.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Carisma Therapeutics PE Ratio?
The Carisma Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Carisma Therapeutics?
Carisma Therapeutics' management team is headed by:
- Jay Duker - NEC
- Thomas Cannell - PRE
- Monica Forbes - CFO
- Glen MacDonald - CTO
- Elly Ryu - CAO
- Mark Sullivan - GCN
- Peter Honig - DRC
- Michael Jewett - DRC
- Carrie Bourdow - IND
- Jason Keyes - IND